Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZURA with free AI briefings, catalyst countdowns, and dilution alerts.

ZURA · Zura Bio Limited

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$187.7M Cash on Hand
CF+ Cash Runway
11.7% Short Interest
$8 Analyst Target (5)
Follow ZURA by email Get an email when ZURA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZURA, unsubscribe in one click. Privacy

📣 What ZURA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tibulizumab Systemic Sclerosis (SSc) Phase 2 · NCT06843239 Active not recruiting
Tibulizumab Dose A Hidradenitis Suppurativa (HS) Phase 2 · NCT06993610 Active not recruiting
Tibulizumab Dose B Hidradenitis Suppurativa (HS) Phase 2 · NCT06993610 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZURA holds $187.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 14 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZURA files for a raise →

👥 Who Owns ZURA

Insiders 23.4% Other 5%+ holders 10.2% Institutions (149 holders) 66.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Athanor Capital
10% owner
Insider 11,581,402 12.02% 2026-01-23
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 9,816,384 10.19% 2026-03-31
Suvretta Capital Management, LLC Institution (13G, 5%+) 9,524,263 9.89% 2026-03-31
Montanova Capital LLC Institution (13F) 9,443,001 9.80% 2026-09-30
AI Biotechnology LLC
10% owner
Insider 6,552,725 6.80% 2026-02-26
Venrock Adviser, LLC Institution (13F) 6,434,990 6.68% 2026-09-30
MPM Bioimpact LLC Institution (13F) 4,449,671 4.62% 2026-09-30
Someit Sidhu
Director · +51,000 options
Insider 4,236,345 4.40% 2024-12-31
Great Point Partners LLC Institution (13F) 4,077,256 4.23% 2026-09-30
Siren, L.L.C. Institution (13F) 3,734,866 3.88% 2026-09-30
Blackrock Inc. Institution (13F) 3,699,932 3.84% 2026-09-30
Commodore Capital Lp Institution (13F) 3,250,000 3.37% 2026-09-30

Share count 96,325,411 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-17
filed 2026-06-22
Thiara Parvinder
Option award (A) 51,000 – –
2026-06-17
filed 2026-06-22
Schoch Steven J
Option award (A) 51,000 – –
2026-06-17
filed 2026-06-22
Eisner Mark
Option award (A) 51,000 – –
2026-06-17
filed 2026-06-22
Becker Daniel J.
Option award (A) 51,000 – –
2026-06-17
filed 2026-06-22
Jarrett Jennifer
Option award (A) 51,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ZURA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZURA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.